Literature DB >> 16763980

Prognosis of Parkinson's disease: time to stage III, IV, V, and to motor fluctuations.

Kenichi Sato1, Taku Hatano, Kazuo Yamashiro, Maki Kagohashi, Kenya Nishioka, Nana Izawa, Hideki Mochizuki, Nobutaka Hattori, Hideo Mori, Yoshikuni Mizuno.   

Abstract

We report a long-term outcome on a large cohort of Japanese patients with Parkinson's disease (PD). A total of 1,768 (793 men, 975 women) consecutive patients visited our clinic from 1 January 1989 to 31 December 2002. Among them, 1,183 patients (531 men, 652 women) came to our clinic within 5 years from the onset of disease and at the Hoehn & Yahr Stage III or less at the first visit. Long-term outcome was evaluated in this subcohort of the patients. We examined the duration to reach Stage III, IV, and V, and the duration to develop wearing off and dyskinesia. Time to reach Stage III was slightly but significantly shorter in women, in that 23.8% of men and 35.3% of women reached Stage III by the end of the 5th year; 49.7% of men and 63.3% of women reached Stage III by the end of the 10th year, and 88.9% of men and 79.9% of women by the end of the 15th year (P < 0.001). Also, durations to develop wearing off and dyskinesia were shorter in women compared to men. These data suggest that the disease progression may be slightly faster for women. Young-onset patients showed significantly longer duration to reach Stage III, IV, and V but shorter duration to develop wearing off and dyskinesia. Not many studies are available in the literature on the long-term outcome of PD, and our data would be useful as a reference. (c) 2006 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16763980     DOI: 10.1002/mds.20993

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  31 in total

Review 1.  Missing pieces in the Parkinson's disease puzzle.

Authors:  Jose A Obeso; Maria C Rodriguez-Oroz; Christopher G Goetz; Concepcion Marin; Jeffrey H Kordower; Manuel Rodriguez; Etienne C Hirsch; Matthew Farrer; Anthony H V Schapira; Glenda Halliday
Journal:  Nat Med       Date:  2010-05-23       Impact factor: 53.440

2.  Sex and Parkinson's disease: a world of difference?

Authors:  David J Burn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-08       Impact factor: 10.154

3.  Efficacy and safety of pramipexole in restless legs syndrome.

Authors:  John C Morgan; Kapil D Sethi
Journal:  Curr Neurol Neurosci Rep       Date:  2007-07       Impact factor: 5.081

Review 4.  A systematic review of loss of independence in Parkinson's disease.

Authors:  Angus D Macleod; J W Kerr Grieve; Carl E Counsell
Journal:  J Neurol       Date:  2015-07-15       Impact factor: 4.849

Review 5.  An update on the diagnosis and treatment of Parkinson disease.

Authors:  Philippe Rizek; Niraj Kumar; Mandar S Jog
Journal:  CMAJ       Date:  2016-05-24       Impact factor: 8.262

Review 6.  The relevance of gender in Parkinson's disease: a review.

Authors:  Marina Picillo; Alessandra Nicoletti; Vincenza Fetoni; Barbara Garavaglia; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2017-01-04       Impact factor: 4.849

7.  Evidence for gender-specific transcriptional profiles of nigral dopamine neurons in Parkinson disease.

Authors:  Filip Simunovic; Ming Yi; Yulei Wang; Robert Stephens; Kai C Sonntag
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

Review 8.  Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease?

Authors:  Julia Heller; Imis Dogan; Jörg B Schulz; Kathrin Reetz
Journal:  Aging Dis       Date:  2013-10-22       Impact factor: 6.745

9.  Evolutionary demographic models reveal the strength of purifying selection on susceptibility alleles to late-onset diseases.

Authors:  Samuel Pavard; Christophe F D Coste
Journal:  Nat Ecol Evol       Date:  2021-01-04       Impact factor: 15.460

10.  Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change.

Authors:  Xuehan Ren; Jeffrey Lin; Glenn T Stebbins; Christopher G Goetz; Sheng Luo
Journal:  Mov Disord       Date:  2021-07-30       Impact factor: 10.338

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.